Nano-antibodies or nAbs are single-domain antibodies derived from camelids that have advantages over traditional antibodies like smaller size, higher affinity and specificity, and stability. Current nAb targets include fluorescent proteins and cytokines. nAbs are available in different formats like agarose resin, magnetic beads, and polyacrylamide resin. Common applications of nAbs include quantitative immunoprecipitation, ChIP, identifying interacting proteins, and RNA immunoprecipitation. The company has been developing nAbs since 2008 and now produces several nAbs for fluorescent proteins with plans to generate hundreds more. Protocols are available for using nAbs in co-immunoprecipitation, chromatin immunoprecipitation, and single molecule pulldown.

1. m.sobika
III-b.sc biotech

2. DEFINITION:
 Nano-Antibodies or “nAb” are single-domain VHH
antibodies derived from camelidae (camels ,
llamas,alpacas , etc .).
 Compared with conventional monoclonal and polyclonal
antibodies, nAb antibodies have the following advantages:
 Small size(app 15 kd)
 High affinity(frequently nanomolar range )
 High specificity
 Unsurpassed stability

3. CURRENT nAb TARGET:
 mNeonGreen-nAb
 GFP-nAb
 RFP-nAb
 mTFP-nAb
 TNFa-nAb
 bFGF-nAb
 bFGF-nAb
 p16-nAb
 VEGF-nAb

4. CURRENT nAb FORMAT:
 Agarose Resin - High binding capacity
 Agarose Spin Kit - Fast, convenient, and consistent protocol
 Magnetic Beads - Fast protocol harnessing a magnetic stand
 Polyacrylamide resin - Durable, reusable, FPLC-compatible
resin with a high flow rate.

5.  Why Should You Choose nAb?
 nAb antibodies are robust tools for a number of biological assays and applications
due to their high affinity and binding specificity, allowing for clean pulldown of
your target protein/fusion with essentially zero background. Some of the most
common applications of nAb include:
 Quantitative Immunoprecipitation
 ChIP-CHIP assays
 Identifying Interacting Proteins
 RIP Assays (RNA Immunoprecipitation)
 CLIP Assays (in vivo Cross Linking and Immunoprecipitation)

7.  History of nAb Development
 Allele's involvement in the field of VHH antibodies goes back a number of
years to 2008, when we first began to examine and appreciate the unmatched
potential of nano-antibodies. In 2009, we introduced GFP-trap along with
other VHH products to the US market through our distribution deal with
Chromotek. Moving forward to 2011, we received NIH funding to carry out a
research and development project exploring alternative VHH antibody
development and isolation technology. Shortly after, we introduced our
custom camelid antibody service, harnessing the latest technology and
techniques to generate unique single domain antibodies for our customers.

8.  In 2012, we moved into a new, two-story facility in San
Diego with a dedicated antibody screening area,
drastically increasing our internal research and custom
service capacity. In anticipation of the expiration of a
fundamental patent on single chain antibodies, we
received investment earlier this year (2013) from Dr. Eric
Xu, co-founder of Baidu and owner of the venture group
Yifang. With these funds we have kicked off an ongoing
effort to generate hundreds of nano-antibodies under the
nAb trademark. Our first nAb products will be
mNeonGreen-nAb™, mWasabi-nAb™ and GFP-nAb™, with
many more to follow

9. nAb Application Protocols:
 nAb for CoIP
 nAb for ChIP
 nAb for SiMPull (Single Molecule Pulldown)